Drugs / MVA-BN-Filo
MVA-BN-Filo
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT02860650 | Aug 2016 → May 2017 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02376400 | Apr → Dec 2015 | — | Crucell Holland BV | Completed | No outcome recorded |
| Phase 1 | NCT02376426 | Mar → Sep 2015 | — | Crucell Holland BV | Completed | No outcome recorded |
| Phase 1 | NCT02325050 | Jan → Jul 2015 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02313077 | Dec 2014 → Apr 2015 | — | Crucell Holland BV | Completed | No outcome recorded |
| Phase 1 | NCT02267109 | Oct 2014 → Apr 2016 | Ebola hemorrhagic fever | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT02240875 | Sep 2014 → Aug 2017 | Ebola hemorrhagic fever | University of Oxford | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05284097 | Sep 2022 → Mar 2023 | Ebola hemorrhagic fever | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03929757 | Aug 2019 → Aug 2022 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT02876328 | Mar 2017 → Dec 2019 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02598388 | Dec 2015 → Dec 2018 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT02564523 | Nov 2015 → Feb 2019 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT02416453 | Jun 2015 → Jan 2018 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT04556526 | Oct 2020 → Mar 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT04228783 | Feb 2020 → Apr 2022 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT04152486 | Nov 2019 → Jan 2022 | Ebola hemorrhagic fever | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| Phase 3 | NCT02661464 | May 2016 → Dec 2021 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Terminated | No outcome recorded |
| Phase 3 | NCT02509494 | Sep 2015 → Jun 2019 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT02543567 | Sep 2015 → Jun 2016 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT02543268 | Sep 2015 → Jan 2016 | — | Crucell Holland BV | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN Filo | “BACKGROUND: The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical development of replication-defective chimpanzee adenovirus 3...” PMID 26546548 ↗ Nov 201524“A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen...” NCT04228783 ↗ “The novel 2-dose heterologous Adenovirus type 26.ZEBOV (Ad26.ZEBOV) and modified vaccinia Ankara-BN-Filo (MVA-BN-Filo) vaccine regimen is safe and provides specific immunity...” PMID 32315287 ↗ Jul 2020 “Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults” NCT02376400 ↗ “a Single Batch of MVA-BN®-Filo in Healthy Adult Subjects” NCT02543268 ↗ |
| Known as | Modified Vaccinia Ankara (MVA)-BN-Filo | “MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus...” NCT04152486 ↗ |
| Known as | modified vaccinia Ankara-BN-Filo | “The novel 2-dose heterologous Adenovirus type 26.ZEBOV (Ad26.ZEBOV) and modified vaccinia Ankara-BN-Filo (MVA-BN-Filo) vaccine regimen is safe and provides specific immunity...” PMID 32315287 ↗ Jul 2020 |
| Known as | MVA-mBN226B | “MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus...” NCT04152486 ↗ |
| Modality | Vaccine | “The purpose of this study is to assess two new Ebola vaccines: cAd3-EBO Z at 3 different doses, and a second vaccine, MVA-BN® Filo, at 3 different doses.” NCT02240875 ↗ |
| Route | Intramuscular | “IM injection of Booster-MVA-BN® Filo or saline placebo” NCT02267109 ↗ |